Furthermore, we found that the EZH2 expression levels in liver cancers at advanced clinicopathological stages were significantly higher than those in tumors at early stages, implying that increased EZH2 expression may indicate tumor progression in these patients. This evidence concerns the gene EZH2 and liver cancer.